Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus induction chemotherapy and concurrent chemoradiotherapy in limited-stage esophageal small cell carcinoma
ChiCTR2500110136Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in small cell carcinoma of the esophagus (SCEC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival (PFS) assessed by independent review committee. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on ChiCTR2500110136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110136.